**M3 Literature Review**

**Period: 08/04/2025 – 08/05/2025**

[Scientific Highlights: 1](#_Toc143520007)

[Clostridioides difficile/ Clostridium difficile 3](#_Toc143520008)

[Fidaxomicin & Clostridium difficile 4](#_Toc143520009)

[Clostridioides difficile vaccine 4](#_Toc143520010)

[Vancomycin & CDI 4](#_Toc143520011)

[CDI 4](#_Toc143520012)

[FMT/ Fecal Microbiota Transplant 5](#_Toc143520013)

[Competitors 5](#_Toc143520014)

[CDAD 6](#_Toc143520015)

[CMC 6](#_Toc143520016)

[Guidelines 6](#_Toc143520017)

[Non-toxigenic C. difficile 6](#_Toc143520018)

[MGB 6](#_Toc143520019)

[Other news of possible interest 7](#_Toc143520020)

Scientific Highlights:

1. Impact of sulfonamide allergy label on clinical outcomes of acute cystitis: a retrospective matched cohort study.
2. Subgroup analyses in randomized trials of Clostridioides difficile associated disease: Recurring Challenges with Analyzing Recurrence.
3. Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.
4. Integrating Clinical Guidelines With ChatGPT-4 Enhances Its' Skills.
5. Clinical translation of microbiome research.
6. RCPE in association with the American College of Gastroenterology and the Scottish Society of Gastroenterology - Gastroenterology: A global perspective.
7. Metronidazole-ursodeoxycholic acid bifunctional antibacterial: A promising strategy to combat Clostridium difficile infection and prevent recurrence.
8. Isolated Adult Gastrointestinal Tract Langerhans Cell Histiocytosis-Report of Two Rare Patients with Review of Literature.
9. Primary solitary pituitary stalk abscess: case report and review.
10. Extended-pulsed Fidaxomicin Therapy for Recurrent Clostridioides difficile Infection After Standard Vancomycin and Fidaxomicin Failure: A Case Report.
11. Efficacy and Safety of Fecal Microbiota Transplant for Prevention of Recurrent Clostridioides difficile Infection.
12. FMT for Recurrent Clostridioides difficile Infection.
13. Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape.
14. Management of severe and fulminant Clostridioides difficile infection in adults.
15. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis.
16. Anatomic Factors Influencing a Persistent J-Sign After Medial Patellofemoral Ligament Reconstruction and Distal Tibial Tubercle Osteotomy in Patients With Recurrent Patellar Dislocations and Patella Alta: A Retrospective Cohort Study.
17. Factors associated with failure of fecal microbiota transplant for recurrent Clostridioides difficile infection.
18. Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA(®)) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
19. Clinical and Microbiological Characteristics of Hospitalized Adults Aged ≤ 45 Years With Clostridioides (Formerly Clostridium) difficile Infection: A Prospective Observational Cohort Study From Hungary.
20. Partial Courses of Fidaxomicin Followed by Oral Vancomycin and the Effect on Recurrence of Clostridioides difficile Infections.

Clostridioides difficile/ Clostridium difficile

1. Exploring the Connection of Health Disparities and Inequities with Healthcare-Acquired Infections in North America: A Scoping Review of the Literature.
2. [Analysis of clinical characteristics and related risk factors of patients with Clostridioides difficile infection in the intensive care unit].
3. Proton pump inhibitors and the risk of Clostridioides difficile infection: A systematic review and dose-response meta-analysis.
4. Human Milk Oligosaccharide Lacto-N-Neotetraose Promotes Gut Microbiota Recovery in the Context of Antibiotic-Induced Dysbiosis.
5. Global, regional, and national burdens of Clostridioides difficile infection over recent decades: a trend analysis informed by the Global Burden of Disease Study.
6. Clinical Outcome of Inflammatory Bowel Disease with Clostridioides difficile Polymerase Chain Reaction Toxin-Positive/Enzyme Immunoassay Toxin-Negative: A Retrospective Cohort Study.
7. Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile.
8. Co-Colonization of Non-difficile Clostridial Species in Antibiotic-Associated Diarrhea Caused by Clostridioides difficile.
9. The Impact of Diet on Clostridioides difficile Infection: A Review.

Fidaxomicin & Clostridium difficile

1. Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.
2. Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.
3. Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.
4. The effects of repeated fecal transplantation and activated charcoal treatment on gut dysbiosis induced by concurrent ceftriaxone administration in mice.
5. Fecal Microbiota Transplantation in Clostridioides Difficile Infections: Rethinking the Approach by Patient Profile in Light of New Evidence.
6. Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for C. Difficile Infection.
7. Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy.
8. Fecal microbiota transplantation: a tale of two regulatory pathways.
9. Translational strategies for oral delivery of faecal microbiota transplantation.
10. The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies.

Clostridioides difficile vaccine

1. Interventions and adaptations to strengthen data quality and use for COVID-19 vaccination: a mixed methods evaluation.
2. Synthesis of PSI Oligosaccharide for the Development of Total Synthetic Vaccine against Clostridium difficile.
3. Protocol to measure the impact of Clostridioides difficile toxins on antibody responses using ELISA, ELISPOT, and toxin-neutralization assays.

Vancomycin & CDI

1. Clostridioides difficile infection in aged mice decreases memory function, which can be protected with alanyl-glutamine supplementation.
2. Fidaxomicin's Role in Overcoming Vancomycin Failure in Clostridium difficile Infections: A Case Series and Literature Review.
3. Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium-Severe Clostridioides Difficile Infection.
4. Potent Antimicrobial Activity of Aspergillus oryzae Fermentate Against Toxigenic Strains of Clostridioides difficile.
5. Lactiplantibacillus plantarum GMNL-661 Ameliorates Clostridioides difficile Infection and Reconfigures Intestinal Microbiota in a Murine Model.

CDI

1. Association Between Antimicrobials and Pump Proton Inhibitors Consumption with the Incidence of Nosocomial Clostridiodes difficile Infection in High Complexity Hospitals in Costa Rica.

FMT/ Fecal Microbiota Transplant

1. Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.
2. Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.
3. Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.
4. The effects of repeated fecal transplantation and activated charcoal treatment on gut dysbiosis induced by concurrent ceftriaxone administration in mice.
5. Fecal Microbiota Transplantation in Clostridioides Difficile Infections: Rethinking the Approach by Patient Profile in Light of New Evidence.
6. Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for C. Difficile Infection.
7. Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy.
8. Fecal microbiota transplantation: a tale of two regulatory pathways.
9. Translational strategies for oral delivery of faecal microbiota transplantation.
10. The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies.

Competitors

1. Patient Personality Influences Early Satisfaction Following Primary Total Hip and Knee Arthroplasty.
2. Contributions of major tau kinase activation and phospho-tau accumulation to cortical and hippocampal tangle formation and cognition in older adults.
3. Patients Excluded from BEST-CLI were More Likely to Undergo a Major Amputation at a Single Urban Safety Net Hospital.
4. Antimicrobial activity of tebipenem to Escherichia coli isolates from outpatients with complicated urinary tract infections.
5. Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.

CDAD

1. Global and regional trends in Clostridioides difficile infection: an analysis from 1990 to 2021.
2. Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients.
3. Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.
4. Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis.
5. Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the Coronavirus Disease 2019 Pandemic.
6. Association of Clostridium difficile infection with clinical outcomes of patients with inflammatory bowel disease: A meta-analysis.
7. Global Patterns of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Prevalence, Epidemiology, and Risk Factors.

CMC

Guidelines

1. From glitter to gold: recommendations for effective dashboards from design through sustainment.
2. An Epidemiological Survey of Sepsis in a Tertiary Academic Hospital from Southwestern Romania.
3. Exploring the Efficacy of Hypochlorous Acid as a Cost Effective Environmental Decontaminant in Dentistry: A Scoping Review.
4. Extended oral antibiotics in primary and revision total joint arthroplasty: An update.
5. Pediatric long COVID: relationships with premorbid history of anxiety or depression and health-related quality of life.

Non-toxigenic C. difficile

1. Clostridioides (Clostridium) difficile in hospitalised children in Cambodia.
2. Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: a retrospective study.

MGB

Other news of possible interest